Twice‐daily compared with once‐daily insulin glargine in people with Type 1 diabetes using meal‐time insulin aspart
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims To compare blood glucose control when using insulin glargine twice daily at breakfast‐ and dinner‐times with insulin glargine once daily at dinner time, in unselected people with Type 1 diabetes using insulin aspart at meal‐times. Methods In this 8‐week, two‐way, cross‐over study, 20 people with Type 1 diabetes were randomized to insulin glargine injection once daily at dinner‐time or twice daily at breakfast‐ and dinner‐times, both plus meal‐time insulin aspart. Each 4‐week treatment period concluded with a 24‐h inpatient metabolic profile. Results Insulin doses, HbA 1c, fructosamine concentration and pre‐breakfast self‐monitored blood glucose (SMBG) concentration did not differ between treatment periods. SMBG concentrations after breakfast, after lunch and before dinner were lower with twice‐daily compared with once‐daily dinner‐time glargine [9.3 ± 0.5 (± se) vs. 6.7 ± 0.5 mmol/l, P = 0.003; 10.2 ± 0.9 vs. 7.0 ± 0.9 mmol/l, P = 0.024; 9.6 ± 0.5 vs. 6.6 ± 0.5 mmol/l, P = 0.001]. Mean 24‐h SMBG concentration was lower with twice‐daily glargine (7.1 ± 0.5 vs. 8.8 ± 0.5 mmol/l, P = 0.031). Within‐day variability of SMBG concentration was lower with twice‐daily glargine (sd 3.2 ± 0.2 vs. 4.0 ± 0.3 mmol/l, P = 0.044). Plasma free insulin concentration was higher in the afternoon with twice‐daily glargine (21.9 ± 1.4 vs. 16.1 ± 1.3 mU/l, P = 0.009), but lower overnight (12.1 ± 1.7 vs. 17.8 ± 1.7 mU/l, P = 0.030), compared with once‐daily injection. Plasma glucose concentration overnight was higher with twice‐daily compared with once‐daily glargine (mean 9.0 ± 0.4 vs. 6.6 ± 0.4 mmol/l, P = 0.001). Conclusions Blood glucose concentration rises in the late afternoon in association with falling plasma insulin levels towards the end of the 24‐h period after insulin glargine injection in some people with Type 1 diabetes using once‐daily glargine at dinner‐time plus a rapid‐acting insulin analogue at meal‐times. This is prevented by twice‐daily injection of insulin glargine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Raskin, P., Klaff, L., Bergenstal, R., Hallé, J. P., Donley, D., & Mecca, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1666 · Cited by 250
Pieber, T. R., Eugène-Jolchine, I., & Derobert, E. (2000) · Diabetes Care · doi:10.2337/diacare.23.2.157 · Cited by 224
Clore, J. N., Nestler, J. E., & Blackard, W. G. (1989) · Diabetes · doi:10.2337/diabetes.38.3.285 · Cited by 62
Ashwell, S. G., Gebbie, J., & Home, P. D. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01726.x · Cited by 53
Self-citation
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“When glargine and detemir are administered in high doses, both show a peak on pharmacokinetic and pharmacodynamics profile [211] ; also there is still interindividual variability and low doses are insufficient to cover a 24-h period [212] .”
BackgroundKlein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251
The evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
“Glargine is given once daily in most patients, but in some instances it may need to be given twice daily (44).”
BackgroundTricco, A. C., Ashoor, H. M., Antony, J., Beyene, J., Veroniki, A. A., Isaranuwatchai, W., Harrington, A., Wilson, C., Tsouros, S., Soobiah, C., et al. (2014) · BMJ · doi:10.1136/bmj.g5459 · Cited by 117
Metadata
- Authors
- Ashwell, S. G., Gebbie, J., & Home, P. D.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2006-05-25
- Volume
- 23
- Issue
- 8
- Pages
- 879-886
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2059989157
- Cited by
- 109
- References
- 5
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Twice‐daily compared with once‐daily insulin glargine in people with Type 1 diabetes using meal‐time insulin aspart. https://app.cochat.ai/papers/10.1111/j.1464-5491.2006.01913.x
- The paper
- Ashwell, S. G., Gebbie, J., & Home, P. D. (2006). Twice‐daily compared with once‐daily insulin glargine in people with Type 1 diabetes using meal‐time insulin aspart. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2006.01913.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.